Cognitive · CNTF-mimetic peptide · Compounded 503A
P21: a CNTF-derived peptide for hippocampal neurogenesis.
P21 is a small synthetic peptide modeled on a critical region of ciliary neurotrophic factor (CNTF). In rodent models it crosses the blood-brain barrier and stimulates new neuron formation in the hippocampus — the brain region most associated with memory and most vulnerable to age-related decline.
Free shipping over $150 · Pay with card or crypto
What P21 is
P21 is an 11-amino-acid peptide engineered by researchers studying the active region of ciliary neurotrophic factor (CNTF). CNTF itself is a large protein with broad effects (and historical tolerability problems in trials); P21 was designed to preserve the neurogenic signal while dropping the bulk and side-effect profile.
In published rodent work it crosses the blood-brain barrier when delivered peripherally and increases the production of new neurons in the dentate gyrus of the hippocampus.
P21 is investigational. It is not FDA-approved. Any U.S. use is off-label, compounded by licensed 503A pharmacies under physician prescription.
How it works
P21 activates the CNTF receptor complex (LIF-Rβ and gp130) downstream, triggering JAK-STAT3 signaling — a pathway central to neural stem-cell proliferation and survival.
In hippocampal models this translates to increased dentate-gyrus neurogenesis, improved synaptic plasticity markers, and improved performance on memory tasks in aged or Alzheimer-model mice.
Unlike native CNTF, P21 does not appear to drive the muscle and weight-loss side effects that hampered earlier CNTF trials.
What patients use it for
Hippocampal neurogenesis
Rodent studies show increased new-neuron formation in the dentate gyrus — the brain region most associated with memory.
Cognitive performance
Improved performance on hippocampal-dependent memory tasks in aged and Alzheimer-model rodents.
Neuroprotection
Studied as a protective signal in models of neurodegeneration and chemotherapy-induced cognitive impairment.
Evidence summary
Chohan MO et al. (Neurobiology of Aging, 2011) demonstrated that P21 enhances neurogenesis and cognition in aged mice.
Bolognin S et al. (Neurobiology of Aging, 2014) showed P21 prevents memory and synaptic deficits in a triple-transgenic Alzheimer model.
Khatoon S et al. (J Alzheimers Dis, 2015) extended the work showing rescue of cognitive function in tau-pathology models.
Human clinical evidence is not yet available. All published data is preclinical.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
No FDA-approved human dosing exists. Compounded protocols in U.S. clinical practice typically use low-microgram subcutaneous dosing several times per week.
Cycles of 8–12 weeks with periodic reassessment are common.
A kindr physician determines whether a trial is appropriate based on goals, age, cognitive baseline, and other medications.
Safety and contraindications
Limited human safety data. Preclinical toxicity studies have not flagged major issues at therapeutic doses.
Not for use in pregnancy, breastfeeding, active cancer, or pediatric populations.
Compounded by licensed 503A pharmacies; not FDA-approved.
Who it's typically considered for
- Adults pursuing physician-supervised cognitive longevity protocols
- Patients with subjective cognitive decline who want a research-stage neurogenic peptide layered with proven interventions
- Patients already optimized on sleep, HRT, exercise, and conventional nootropics
Frequently asked questions
Is P21 the same as CNTF?
No — P21 is a small synthetic fragment that mimics part of CNTF activity while avoiding the side-effect profile of the full protein.
Has P21 been tested in humans?
Not in published clinical trials. All efficacy data is preclinical (rodent). U.S. use is investigational and compounded.
P21 vs Dihexa or Cerebrolysin?
P21 specifically targets the CNTF-neurogenesis axis. Dihexa is an angiotensin IV analog focused on synaptogenesis. Cerebrolysin is a complex hydrolysate with broad neurotrophic activity.
How is it administered?
Subcutaneous injection — frequency and dose set by your prescribing physician.
Is it safe?
Preclinical safety looks favorable; long-term human data does not yet exist. Physician supervision required.
Sources
- Chohan MO et al. Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. Neurobiol Aging (2011). — pubmed.ncbi.nlm.nih.gov/20557975
- Bolognin S et al. An experimental rat model of sporadic Alzheimer-like disease... rescued by P21. Neurobiol Aging (2014). — pubmed.ncbi.nlm.nih.gov/24239383
- Iqbal K, Bolognin S, Wang X, Basurto-Islas G, Blanchard J, Tung YC. Animal models of the sporadic form of Alzheimer disease (P21 work). Curr Alzheimer Res (2013). — pubmed.ncbi.nlm.nih.gov/23278678
Considering P21?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Related peptides
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026
Last reviewed July 3, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.